{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:44:47Z","timestamp":1765889087830,"version":"3.40.5"},"reference-count":11,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BTT"],"DOI":"10.2147\/btt.s400073","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T03:20:05Z","timestamp":1681960805000},"page":"57-60","source":"Crossref","is-referenced-by-count":2,"title":["Hypereosinophilic Dermatitis: Successful Treatment with Dupilumab"],"prefix":"10.2147","volume":"Volume 17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8824-922X","authenticated-orcid":true,"given":"Chenyu","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianzhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7198-0822","authenticated-orcid":true,"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,4]]},"reference":[{"key":"ref1","unstructured":"Regeneron. Dupixent\u00ae (dupilumab) prescribing information. Important legal document for physicians prescribing dupilumab; 2017."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jdcr.2020.02.030","volume":"6","author":"Wieser","year":"2020","journal-title":"JAAD Case Rep"},{"key":"ref3","unstructured":"Regeneron Pharmaceuticals Inc. Regeneron and sanofi announce FDA approval of DUPIXENT\u00ae (dupilumab), the first targeted biologic therapy for adults with moderate-to-severe atopic dermatitis. PR Newswire.2017."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1001\/jamadermatol.2018.3912","volume":"155","author":"Beck","year":"2019","journal-title":"JAMA Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e13222","DOI":"10.1111\/dth.13222","volume":"33","author":"Holm","year":"2020","journal-title":"Dermatol Ther"},{"key":"ref6","first-page":"13222","volume":"25","author":"Seidman","year":"2019","journal-title":"Dermatol Online"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1056\/NEJMoa2205982","volume":"387","author":"Dellon","year":"2022","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1053\/j.gastro.2019.09.042","volume":"158","author":"Hirano","year":"2020","journal-title":"Gastroenterology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/13543784.2017.1282458","volume":"26","author":"Santini","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1080\/17512433.2018.1449642","volume":"11","author":"Seegr\u00e4ber","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1016\/j.jaci.2009.11.017","volume":"125","author":"Stone","year":"2010","journal-title":"J Allergy Clin Immun"}],"container-title":["Biologics: Targets and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=89120","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=89120","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T03:20:10Z","timestamp":1681960810000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/hypereosinophilic-dermatitis-successful-treatment-with-dupilumab-peer-reviewed-fulltext-article-BTT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":11,"URL":"https:\/\/doi.org\/10.2147\/btt.s400073","relation":{},"ISSN":["1177-5491"],"issn-type":[{"type":"electronic","value":"1177-5491"}],"subject":[],"published":{"date-parts":[[2023,4]]}}}